There are more than 200 distinct types of cancer, and the number keeps growing as scientists learn to distinguish cancers by their genetic makeup rather than just where they appear in the body. The World Health Organization’s official classification, now in its 6th edition across 14 volumes, catalogs every known cancer type and subtype. But understanding the number is less useful than understanding how cancers are organized, because that structure determines how they’re diagnosed and treated.
Five Major Categories
Every cancer falls into one of five broad groups based on the type of cell it starts in. This is the most fundamental way oncologists sort cancers apart.
Carcinomas start in epithelial cells, the tissue that lines your skin, organs, and internal passageways like the digestive tract. They account for 80 to 90 percent of all cancer cases, making them by far the most common category. Carcinomas split into two major subtypes: adenocarcinomas, which develop in organs or glands, and squamous cell carcinomas, which originate in flat surface cells. Most breast, lung, prostate, and colorectal cancers are carcinomas.
Sarcomas arise in connective and supportive tissues: bones, cartilage, muscle, fat, and blood vessels. They’re far less common than carcinomas. Within this group you’ll find bone cancers (osteosarcoma), cancers of smooth muscle, skeletal muscle, fat tissue, fibrous tissue, and even the connective tissue in the brain.
Leukemias are cancers of the bone marrow and blood. They’re sometimes called “liquid cancers” because the malignant cells circulate through the bloodstream rather than forming solid tumors. Leukemia typically involves the overproduction of immature white blood cells and is further divided by which white blood cell lineage is affected.
Lymphomas develop in the lymphatic system, the network of nodes, vessels, and organs (including the spleen, tonsils, and thymus) that produce infection-fighting white blood cells. Unlike leukemia cells, lymphoma cells tend to cluster together and form solid masses in lymphatic tissue. The two main divisions are Hodgkin lymphoma and non-Hodgkin lymphoma.
Myelomas originate in the plasma cells of bone marrow. Plasma cells normally produce antibodies, so myeloma disrupts the body’s ability to fight infection and can damage bones where the marrow is affected.
The Most Common Types in the U.S.
Roughly 2.1 million people will be diagnosed with cancer in the United States in a single year. The five most frequently diagnosed types, based on projections from the American Cancer Society, are:
- Prostate cancer: about 333,800 new cases per year
- Breast cancer: about 324,600 new cases
- Lung and bronchus cancer: about 229,400 new cases
- Colorectal cancer: about 158,900 new cases
- Melanoma (skin): about 112,000 new cases
These five alone represent more than half of all new diagnoses. All of them are carcinomas except melanoma, which arises from pigment-producing cells in the skin.
Rare Cancers Add Up
A cancer is classified as rare when it affects fewer than 40,000 people per year in the U.S. Individually, each rare cancer is uncommon. Collectively, they account for just over a quarter of all cancer diagnoses. That means roughly one in four people with cancer has a type that most oncologists rarely see, which can make diagnosis slower and treatment options more limited. Examples include cancers of the eye, bile ducts, adrenal glands, and many sarcoma subtypes.
Why the Count Keeps Climbing
The traditional way to classify cancer was straightforward: look at the tumor under a microscope, identify which organ it started in, and describe how the cells appear. That approach gives you the 200-plus types most sources cite. But molecular testing has revealed that what looks like one disease is often several.
Breast cancer is the clearest example. Based on which receptors the tumor cells carry, breast cancer splits into at least four molecular subtypes: luminal A, luminal B, HER2-positive, and triple-negative. Each behaves differently, grows at a different rate, and responds to different treatments. Triple-negative breast cancer, which accounts for about 10 percent of breast cancer cases, lacks all three common receptors and can itself be subdivided into seven further subtypes based on gene expression patterns. This level of detail matters because a treatment that works well for one subtype may do nothing for another.
Genetic mutations drive much of this complexity. Mutations in the BRCA1 and BRCA2 genes, for instance, increase cancer risk by up to 40 percent and are closely tied to triple-negative breast cancer. Other gene mutations affect cell growth pathways in ways that create distinct disease behavior even within cancers that look identical under a microscope. The WHO’s classification system now integrates molecular information alongside traditional microscopic appearance, which is one reason the latest edition expanded from 10 volumes to 14.
Children Get Different Cancers
Childhood cancers are not simply smaller versions of adult cancers. Some types occur almost exclusively in children. Retinoblastoma, a cancer of the eye, develops mainly in young children, and about 45 percent of cases involve an inherited gene variant passed from a parent. Other pediatric cancers include specific types of brain tumors, bone cancers, and blood cancers that differ genetically from their adult counterparts.
In adolescents and young adults, the picture shifts. The most frequently diagnosed cancers in this age group start to overlap with adult cancers, including breast cancer, melanoma, and thyroid cancer. But certain types, like testicular cancer, peak specifically in this age range and are less common in both younger children and older adults.
What Makes a Growth “Cancer”
Not every abnormal growth counts toward this tally. The line between a benign tumor and cancer comes down to behavior. Benign tumors grow slowly, stay contained, and don’t invade surrounding tissue. Cancerous (malignant) tumors grow faster, invade nearby structures, and can break off and spread to distant parts of the body through a process called metastasis. That ability to spread is the defining feature of cancer.
The boundary isn’t always sharp, though. Some benign tumors can become cancerous over time if abnormal cells keep dividing. When cells reproduce faster than normal but still look relatively healthy under a microscope, doctors monitor the growth closely for signs of progression. This gray zone is why regular screening catches cancers that might have started as something harmless.